Rivaroxaban for Heart Attack

University of Alberta, Edmonton, Canada
Heart AttackRivaroxaban 2.5 MG [Xarelto] - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing whether a drug can help prevent major heart problems in people who have had a heart attack.

Eligible Conditions
  • Heart Attack

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2 & 3

Similar Trials

1
Hemorrhagic Myocardial Infarction - Deferiprone
1
Cardiomyopathy
1
PEP in Acute Myocardial Infarction

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: Through study completion, estimated at 1-year

90-days
Number of participants who experience a composite of death, stroke or myocardial infarction
Number of participants who experience major bleeding
Through study completion, estimated at 1-year
Feasibility outcome

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Hemorrhagic Myocardial Infarction - Deferiprone
1
Cardiomyopathy
1
PEP in Acute Myocardial Infarction

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 20 Other Conditions
This treatment demonstrated efficacy for 20 other conditions.

Trial Design

2 Treatment Groups

Rivaroxaban
1 of 2
Placebo
1 of 2

Active Control

Non-Treatment Group

8 Total Participants · 2 Treatment Groups

Primary Treatment: Rivaroxaban · Has Placebo Group · Phase 2 & 3

Rivaroxaban
Drug
ActiveComparator Group · 1 Intervention: Rivaroxaban 2.5 MG [Xarelto] · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, estimated at 1-year

Who is running the clinical trial?

University of AlbertaLead Sponsor
840 Previous Clinical Trials
386,918 Total Patients Enrolled
Michelle Graham, MDPrincipal InvestigatorUniversity of Alberta

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

How many people are the most that can join this clinical trial?

"That is correct. The clinicaltrials.gov website shows that this trial is currently recruiting patients. The trial was posted on April 5th, 2021 and was last updated on May 19th, 2022. The study is looking for 100 patients at 1 location." - Anonymous Online Contributor

Unverified Answer

Is this research project novel in terms of its design or purpose?

"Rivaroxaban's journey through clinical trials began in 2015 with Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma sponsoring the first study. 2180 patients participated in the first Rivaroxaban trial, which resulted in the drug being approved for Phase 3 clinical trials. As of now, there are 61 active clinical trials for Rivaroxaban taking place in 402 cities and 45 countries." - Anonymous Online Contributor

Unverified Answer

What indications does Rivaroxaban usually cover?

"Rivaroxaban is most often used as a treatment for venous thromboembolism, but it can also be given to patients suffering from deep vein thrombosis, chronic coronary artery disease, and cerebrovascular accident." - Anonymous Online Contributor

Unverified Answer

Are patient applications being accepted at this time?

"The clinical trial is currently recruiting participants, with the original posting on 2021-04-05 and the most recent update on 2022-05-19." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top